Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone
Figure 3
Change in total cholesterol and acid-labile subunit (ALS) in the placebo (▲) and the rosiglitazone group (○). for change in total cholesterol by change in ALS over time.